Last reviewed · How we verify
MDD diagnosis and Fluoxetine treatment
MDD diagnosis and Fluoxetine treatment is a Selective Serotonin Reuptake Inhibitor (SSRI) Small molecule drug developed by University of Pennsylvania. It is currently FDA-approved.
Fluoxetine is an antidepressant used in the treatment of major depressive disorder (MDD). It is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce anxiety. The drug is not associated with any FDA label, indicating it may be used off-label or in clinical trials. Common side effects include nausea, headache, and insomnia. The drug has a well-established safety profile but requires careful monitoring in certain populations, such as those with a history of suicidal thoughts.
At a glance
| Generic name | MDD diagnosis and Fluoxetine treatment |
|---|---|
| Sponsor | University of Pennsylvania |
| Drug class | Selective Serotonin Reuptake Inhibitor (SSRI) |
| Target | Serotonin Transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurobiological and Genomic Predictors of Relapse in Depression
- SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project (NA)
- Dapagliflozin in Depression (PHASE1, PHASE2)
- Cellular Aging and Neurobiology of Depression Study (NA)
- Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria (PHASE4)
- Treatment Interrupts Depression Early (PHASE2)
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDD diagnosis and Fluoxetine treatment CI brief — competitive landscape report
- MDD diagnosis and Fluoxetine treatment updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI
Frequently asked questions about MDD diagnosis and Fluoxetine treatment
What is MDD diagnosis and Fluoxetine treatment?
Who makes MDD diagnosis and Fluoxetine treatment?
What drug class is MDD diagnosis and Fluoxetine treatment in?
What development phase is MDD diagnosis and Fluoxetine treatment in?
What does MDD diagnosis and Fluoxetine treatment target?
Related
- Drug class: All Selective Serotonin Reuptake Inhibitor (SSRI) drugs
- Target: All drugs targeting Serotonin Transporter (SERT)
- Manufacturer: University of Pennsylvania — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Compare: MDD diagnosis and Fluoxetine treatment vs similar drugs
- Pricing: MDD diagnosis and Fluoxetine treatment cost, discount & access